Active substance
Results for the substance sofosbuvir velpatasvir
4 results
About this active substance
Sofosbuvir+velpatasvir is a combination of antiviral medications used in the treatment of chronic hepatitis C (HCV) in patients with all genotypes of the virus. This combination works by inhibiting multiple stages of the viral replication cycle, providing a broad-spectrum approach against HCV.
Sofosbuvir is an NS5B polymerase inhibitor, and velpatasvir is an NS5A protein inhibitor. Together, these drugs reduce viral load and enable the elimination of the virus from the body. The treatment is administered orally, usually once daily, for 12 weeks.
Common side effects include headache, fatigue, nausea, and diarrhea. In rare cases, severe adverse reactions such as allergic reactions or liver function impairment may occur. It is important for patients to be monitored during treatment to assess therapeutic response and potential side effects.
Sofosbuvir+velpatasvir represents an advanced therapeutic option for patients with chronic hepatitis C, offering high cure rates and convenient administration.
Sofosbuvir is an NS5B polymerase inhibitor, and velpatasvir is an NS5A protein inhibitor. Together, these drugs reduce viral load and enable the elimination of the virus from the body. The treatment is administered orally, usually once daily, for 12 weeks.
Common side effects include headache, fatigue, nausea, and diarrhea. In rare cases, severe adverse reactions such as allergic reactions or liver function impairment may occur. It is important for patients to be monitored during treatment to assess therapeutic response and potential side effects.
Sofosbuvir+velpatasvir represents an advanced therapeutic option for patients with chronic hepatitis C, offering high cure rates and convenient administration.
-
-
EPCLUSA 200mg/50mg film-coated tablets GILEAD ORIGINAL MEDICINE
-
EPCLUSA 150mg/37.5mg coated granules in sachet GILEAD ORIGINAL MEDICINE
-
EPCLUSA 200mg/50mg coated granules in sachet GILEAD ORIGINAL MEDICINE